Oramed to Host Webinar Highlighting Detailed Safety and Efficacy Data from Its Positive Phase 2 Clinical Trial of ORMD-0801 for NASH with KOL Discussion on Current Treatment Landscape - mailchi.mp/oramed/oramed-… To register for the event, please click here: touchconference.zoom.us/webinar/regist…

Oramed Reports Third Quarter 2022 Financial Results - mailchi.mp/oramed/oramed-… "Oramed remains in a strong financial position with approximately $160 million in cash and investments as of September 30, 2022, allowing us to continue advancing all aspects of our pipeline. $ORMP

Oramed Signs Definitive Deal with Medicox to Commercialize Oral Insulin in South Korea - mailchi.mp/oramed/oramed-… $ORMP #Biotech #Oralinsulin #T2D

Please join us tomorrow for a #webinar highlighting data from our #Phase2 clinical trial or oral insulin for NASH Register here: touchconference.zoom.us/webinar/regist… $ORMP #oralinsulin #NASH

Join us for a #webinar highlighting data from our #Phase2 clinical trial of oral insulin for NASH Register here:

Oramed Announces Additional Positive Safety and Efficacy Data from Its Phase 2 Clinical Trial of ORMD-0801 for NASH - mailchi.mp/oramed/oramed-… The presentation of this new data was featured in a webinar today with a replay available on Oramed’s website. $ORMP #NASH #Biotech

Oramed Announces Publication of Oral Insulin Study in Peer-Reviewed Journal: Diabetes, Obesity, and Metabolism - mailchi.mp/oramed/oramed-… The article can be accessed on Oramed's website under Scientific Articles and Abstracts. $ORMP #oralinsulin #biotech

Check out the highlight video of Oramed’s recent webinar sharing data from its positive phase 2 clinical trial of oral insulin for #NASH with a Key Opinion Leader Discussion on the current treatment landscape. You can see the entire webinar here: youtube.com/watch?v=YRYwZl… $ORMP

Oramed Letter to Shareholders - mailchi.mp/oramed/oramed-… We are entering 2023 with real excitement for what we believe will be a monumental year for the Company starting with expected topline #data from the first of our two P3 #oralinsulin trials in mid-Jan. $ORMP #biotech

Oramed Granted U.S. Combination Therapy Patent for Oral GLP-1 & Insulin - mailchi.mp/oramed/oramed-… With topline data for our first Phase 3 oral insulin trial expected soon, we continue to fortify Oramed’s leading position with respect to intellectual property assets $ORMP #biotech

“We're excited to welcome Ben Shapiro onto our Board of Directors. His talents are expected to bring real value to the Oramed Pharma Board and we're delighted to work with him to build shareholder value,” said Oramed CEO, Nadav Kidron. mailchi.mp/e8c3d1b0e4b8/o…

Oramed announces its Chinese partner successfully completed a Phase 3 oral insulin trial and that Oramed has completed an analysis of its U.S.-based Phase 3 oral insulin trial with significant lowering of A1C levels seen in patient subgroups - mailchi.mp/oramed/oramed-… $ORMP

Oramed to Present at 83rd American Diabetes Association Conference - mailchi.mp/oramed/oramed-… $ORMP #oralinsulin #ADA #T2D #NASH

This week we hosted colleagues from HTIT for ongoing discussions on our Joint Venture. We look forward to working together to bring oral insulin to market in China and beyond. $ORMP #JV #Oralinsulin #Biotech

We're pleased to share this letter to shareholders from our CEO finance.yahoo.com/news/oramed-le… $ORMP

Oramed Pharmaceuticals Announces Restructuring of Scilex Holding Company Debt - mailchi.mp/oramed/oramed-… $ORMP

Oramed Announces Transformative Joint Venture to Accelerate Development and Commercialization of Oral Insulin - mailchi.mp/oramed/oramed-… $ORMP #drugdevelopment #oralinsulin

Oramed Pharmaceuticals Issues Letter to Shareholders mailchi.mp/oramed/oramed-… $ORMP

Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical - mailchi.mp/oramed/oramed-… $ORMP

Oramed Releases Letter to Shareholders, Highlighting Developments in Oral Insulin Program, Significant Investment Appreciation - mailchi.mp/oramed/oramed-… $ORMP